# Study of ALXN2050 in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)

> **NCT05097989** · PHASE2 · TERMINATED · sponsor: **Alexion Pharmaceuticals, Inc.** · enrollment: 100 (actual)

## Conditions studied

- Lupus Nephritis
- Immunoglobulin A Nephropathy
- IgAN
- LN

## Interventions

- **DRUG:** ALXN2050
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05097989
- **Lead sponsor:** Alexion Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-01-14
- **Primary completion:** 2024-12-09
- **Final completion:** 2024-12-09
- **Target enrollment:** 100 (ACTUAL)
- **Why stopped:** Sponsor Decision.
- **Last updated:** 2025-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05097989

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05097989, "Study of ALXN2050 in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05097989. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*